TWAICE
2.9.2021 15:02:11 CEST | Business Wire | Press release
Battery analytics software expert TWAICE today announced a collaboration with Analog Devices, Inc., a global semiconductor and system solutions company, to tackle the challenges of battery lifecycle optimization. The combination of Analog Devices’ sensor technology and wireless connectivity with TWAICE’s battery analytics software will benefit customers in the mobility and energy sectors. The alliance will be instrumental in significantly reducing warranty risks and recalls, optimizing battery life, and enhancing battery value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005016/en/
Analog Devices is a global leader in battery management systems, and high-performance analog, mixed-signal, and digital signal processing solutions. The collaboration with the software company TWAICE, whose platform provides end-to-end battery analytics solutions, will enable the optimization of the entire battery lifecycle.
Mobility is at an inflection point, with electrified powertrains replacing combustion engines. Battery reliability and economics are critical in the widespread deployment of renewable energies and electric vehicles. Battery performance and lifespan play a key role in the sustainability of solutions they are deployed in, yet the assessment thereof is often challenging. “Precision data combined with advanced predictive battery analytics will shed light into the darkness, which is crucial in unlocking as yet undiscovered potential along the entire value chain," said Dr. Stephan Rohr, Co-CEO of TWAICE.
“The battery is the energy source for every electric vehicle, and it is also a valuable asset,” said Patrick Morgan, Vice President of Automotive at Analog Devices. “Together with TWAICE, we are delivering innovative holistic solutions across battery lifetimes that create significant value for our customers and support a circular economy.”
The goal of the collaboration is to provide a holistic lifecycle solution for automakers with integrated hardware and software. Accurate battery measurements provided through a wireless battery management system form the basis. Analog Devices’ sensor technology provides data, and a quality thereof previously unavailable. TWAICE can generate crucial insights into the battery performance desired by companies around the globe. The resulting forecasts enable qualified statements at any point in the battery lifecycle regarding its value and usability.
About Analog Devices Inc.
Analog Devices (ADI), headquartered in Norwood, Massachusetts, is a global leader in the design, manufacture and marketing of a broad portfolio of high-performance analog, mixed-signal, DSP circuits and microchips used in virtually all types of electronic devices. With over 55 years of market experience, 16,000 employees worldwide today, over 4,700 patents and 125,000 customers in instrumentation, automation, communications, healthcare, automotive and numerous other industries, Analog Devices is dedicated to solving technical challenges associated with signal processing in electronic devices. More at www.analog.com .
About TWAICE
TWAICE provides predictive analytics software that optimizes both the development and operation of lithium-ion batteries. As the leading provider of battery analytics software to global electric vehicle and energy companies, TWAICE increases the longevity, efficiency and sustainability of products that drive tomorrow's economy. More at www.twaice.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom